Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404384 | 0.87 | RORC (0.45) | RORCS1PR1S1PR5SCN9AS1PR3 | |
| SCHEMBL1963502 | 0.86 | PARP10 (0.44) | RORCS1PR1S1PR5SCN9AS1PR3 | |
| SCHEMBL1964065 | 0.84 | RORC (0.43) | RORCS1PR1S1PR5SCN9AS1PR3 | |
| SCHEMBL401766 | 0.84 | P2RY12 (0.45) | RORCS1PR1S1PR5SCN9AS1PR3 | |
| SCHEMBL13641427 | 0.84 | S1PR1 (0.37) | S1PR1S1PR5SCN9AS1PR3CNR1 | |
| SCHEMBL17627108 | 0.83 | RORC (0.41) | RORCS1PR1S1PR5SCN9AS1PR3 | |
| SCHEMBL3950931 | 0.83 | S1PR1 (0.42) | RORCS1PR1S1PR5SCN9AS1PR3 | |
| SCHEMBL13012496 | 0.83 | CNR1 (0.38) | S1PR1S1PR5SCN9ACNR1KCNQ3 | |
| SCHEMBL3957207 | 0.82 | S1PR1 (0.41) | RORCS1PR1S1PR5SCN9AS1PR3 | |
| Hydrochloric Acid SCHEMBL27669705 | 0.81 | S1PR1 (0.41) | RORCS1PR1S1PR5SCN9AS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2023-09-19 | — | — | US | disclosed |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| EP-4116294-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-01-11 | — | — | EP | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| EP-2271643-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039889-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | RORC 14/4885S1PR1 2320/4885S1PR5 1843/4885 |
| US-20230126480-A1 | BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF | AZI2, GABBR2, CNDP2 | RORC 356/4885S1PR1 379/4885S1PR5 451/4885 |
| US-11760751-B2 | Benzo 2-azaspiro[4.4]nonane compound and use thereof | AZI2, GABBR2, CNDP2 | RORC 356/4885S1PR1 379/4885S1PR5 451/4885 |
| US-20120283297-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR3, S1PR2 | RORC 344/4885S1PR1 1/4885S1PR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.